Review
Oncology
Borivoj Golijanin, Kamil Malshy, Sari Khaleel, Galina Lagos, Ali Amin, Liang Cheng, Dragan Golijanin, Anthony Mega
Summary: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, and its pathogenesis is mainly caused by biallelic loss of the tumor suppressor gene VHL. Dysfunctional degradation of HIF due to VHL loss leads to overaccumulation of HIF, resulting in the activation of genes responsible for cell survival and proliferation in ccRCC. Previous therapies have targeted downstream effectors of HIF, but there is now a focus on interfering with upstream targets.
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
Hanzhi Dong, Yuan Cao, Yan Jian, Jun Lei, Weimin Zhou, Xiaoling Yu, Xiquan Zhang, Zhiqiang Peng, Zhe Sun
Summary: This study analyzed the impact of nephrectomy on survival in patients with metastatic renal cell carcinoma who received immune-targeted therapy. The results showed that patients who underwent nephrectomy achieved survival benefits, and nephrectomy, clear cell carcinoma, and oligo-organ metastasis were found to be favorable independent prognostic factors.
Review
Biochemistry & Molecular Biology
Haibao Zhang, Guodong Zhu
Summary: Renal cell carcinoma (RCC) is a lethal urologic malignancy with poor prognosis, and surgery is the major treatment method, but metastatic RCC (mRCC) is highly resistant to current therapies. Genetic mutations and signaling pathways play important roles in RCC progression, and recent studies have led to the development of promising drugs and immunotherapies for mRCC treatment.
CURRENT MEDICINAL CHEMISTRY
(2021)
Review
Oncology
Kevin K. Zarrabi, Oladimeji Lanade, Daniel M. Geynisman
Summary: Kidney cancer is a common type of cancer, with clear cell renal cell carcinoma being the most frequent form. Treatment options for newly diagnosed metastatic clear cell renal cell carcinoma include surgery, radiation, and systemic therapies. The complexity of treatment selection has increased due to the diverse biology of tumors. The therapeutic landscape for metastatic renal cell carcinoma has rapidly evolved, with combination therapy strategies involving immune checkpoint blockade and anti-angiogenesis targeted therapy becoming the standard of care.
Article
Urology & Nephrology
Stephanie G. C. Kroeze, Corinna Fritz, Jana Schaule, Shankar Siva, Klaus H. Kahl, Nora Sundahl, Oliver Blanck, David Kaul, Sonja Adebahr, Joost J. C. Verhoeff, Georgios Skazikis, Falk Roeder, Michael Geier, Franziska Eckert, Matthias Guckenberger
Summary: The study evaluated the safety and efficacy of stereotactic radiotherapy in mRCC patients receiving targeted therapy or immunotherapy. The results showed that the combined treatment was safe and effective, with good local metastasis control and survival rates.
Article
Immunology
Ganghua Zhang, Xinyu Chen, Jianing Fang, Panpan Tai, Aiyan Chen, Ke Cao
Summary: The development of immunotherapy has provided more treatment options for advanced kidney renal clear cell carcinoma (KIRC). This study explored the potential role of cuproptosis in KIRC and found that high cuproptosis score is associated with poor prognosis and low efficacy of immune checkpoint inhibitors, but high sensitivity to certain targeted drugs. Additionally, two potential cuproptosis-promoting genes were identified and cuproptosis was confirmed in KIRC cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Ryoko Sawada, Shuichi Fujiwara, Shunsuke Yahiro, Tomohiro Miyamoto, Tomoaki Terakawa, Yutaka Mifune, Yuichi Hoshino, Kenichiro Kakutani, Tomoyuki Matsumoto, Takehiko Matsushita, Takahiro Niikura, Ryosuke Kuroda, Toshihiro Akisue
Summary: The introduction of tyrosine kinase inhibitors has greatly improved treatment strategies for metastatic renal cell carcinoma (RCC) and increased survival rates. However, there is a lack of standardized treatment for bone metastases from RCC after targeted therapy. This study aimed to evaluate the outcomes of palliative surgical treatment for bone metastases in patients with advanced RCC and found that the postoperative results were positive, emphasizing the importance of systemic treatment over local control for advanced bone metastasis in RCC.
Article
Oncology
Daniel Benamran, Laurence Albiges, Axel Bex, Gianluca Giannarini, Umberto Capitanio, Morgan Roupret
Summary: This article focuses on a 73-year-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma and treated with systemic therapy. It discusses current guideline-based treatment options, the role of cytoreductive nephrectomy and metastasis directed therapies in managing metastatic RCC, as well as various systemic targeted and immune therapies choices. Insights into future developments in treatment pathways are also provided.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Weimin Zhong, Hongbin Zhong, Fengling Zhang, Chaoqun Huang, Yao Lin, Jiyi Huang
Summary: This study identified two hypoxia-related molecular subtypes for ccRCC, C1 and C2, with distinct differences in prognosis, immune/stromal scores, and response to immunotherapy and targeted therapy. The C2 subtype exhibited poorer prognosis, higher immune/stromal scores, and greater sensitivity to immunotherapy and targeted therapy, with higher levels of CXCL1/2/3/5/6/8 chemokines. The subtype-specific signature based on differentially expressed genes could independently predict patients' prognosis and assist in personalized prediction of survival probability.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Liliana Eleonora Semenescu, Amira Kamel, Vasile Ciubotaru, Silvia Mara Baez-Rodriguez, Mircea Furtos, Alexandra Costachi, Anica Dricu, Ligia Gabriela Tataranu
Summary: This article summarizes the mechanisms, importance, benefits, adverse events, and efficacy of immunotherapy in metastatic renal cell carcinoma, with a focus on brain metastases.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2023)
Article
Oncology
Carlos Riveros, Sanjana Ranganathan, Jiaqiong Xu, Courtney Chang, Dharam Kaushik, Monica Morgan, Brian J. Miles, Taliah Muhammad, Maryam Anis, Monty Aghazadeh, Jun Zhang, Eleni Efstathiou, Zachary Klaassen, Michael A. Brooks, Brian Rini, Christopher J. D. Wallis, Raj Satkunasivam
Summary: While novel treatment approaches in metastatic ccRCC are well-supported by numerous studies, there is a lack of corresponding data for pRCC. This study aims to compare real-world trends in the utilization of systemic therapy and its impact on OS between metastatic pRCC and ccRCC, using ccRCC as a comparison group.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Review
Oncology
San Hue Hua, Maximillian Viera, George W. Yip, Boon Huat Bay
Summary: Glycosaminoglycans (GAGs) are a class of carbohydrates closely associated with cancer progression. They play important roles in cancer cell growth and signaling, as well as cell migration and invasion, which are crucial for metastasis. This review explores the potential use of GAGs as biomarkers and therapeutic targets for metastatic renal cancer, a disease with poor survival rates and major treatment challenges.
Review
Oncology
Ameish Govindarajan, Daniela V. Castro, Zeynep B. Zengin, Sabrina K. Salgia, Jalen Patel, Sumanta K. Pal
Summary: The treatment landscape of metastatic renal cell carcinoma has changed significantly over the past decade, with doublet immunotherapy and combination therapy becoming the standard of care. This article outlines the important elements and considerations in the treatment of renal cell carcinoma and explores potential treatment options.
Article
Oncology
Yang Liu, Zhiling Zhang, Ruiqi Liu, Wensu Wei, Zitong Zhang, Lixin Mai, Shengjie Guo, Hui Han, Fangjian Zhou, Liru He, Pei Dong
Summary: The study showed that adding stereotactic body radiotherapy (SBRT) to non-first-line programmed death-1 (PD-1) inhibitors and targeted agents (TA) therapy in metastatic renal cell carcinoma patients significantly prolonged overall survival (OS). The addition of SBRT improved OS in patients with clear-cell histology and a longer duration of response to first-line antiangiogenic therapy, with similar rates of grade >= 3 toxicities between the two treatment groups.
RADIATION ONCOLOGY
(2021)
Article
Medicine, General & Internal
T. K. Choueiri, T. Powles, M. Burotto, B. Escudier, M. T. Bourlon, B. Zurawski, V. M. Oyervides Juarez, J. J. Hsieh, U. Basso, A. Y. Shah, C. Suarez, A. Hamzaj, J. C. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, J. P. Feregrino, J. Zolnierek, D. Pook, E. R. Kessler, Y. Tomita, R. Mizuno, J. Bedke, J. Zhang, M. A. Maurer, B. Simsek, F. Ejzykowicz, G. M. Schwab, A. B. Apolo, R. J. Motzer
Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)